GSA Capital Partners LLP Sells 50,667 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

GSA Capital Partners LLP reduced its stake in Protalix BioTherapeutics, Inc. (NYSE:PLX) by 9.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 493,571 shares of the company’s stock after selling 50,667 shares during the period. GSA Capital Partners LLP owned 0.67% of Protalix BioTherapeutics worth $622,000 at the end of the most recent reporting period.

Separately, Bailard Inc. bought a new position in shares of Protalix BioTherapeutics during the fourth quarter valued at approximately $121,000. 16.53% of the stock is owned by institutional investors.

Protalix BioTherapeutics Stock Performance

Shares of NYSE PLX opened at $1.14 on Friday. Protalix BioTherapeutics, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $2.09. The company has a 50 day simple moving average of $1.16 and a two-hundred day simple moving average of $1.34. The company has a market capitalization of $83.58 million, a price-to-earnings ratio of 28.50 and a beta of 0.78.

Protalix BioTherapeutics (NYSE:PLX) last announced its earnings results on Friday, May 10th. The company reported ($0.06) earnings per share for the quarter. Protalix BioTherapeutics had a net margin of 11.48% and a return on equity of 19.48%. The business had revenue of $3.75 million for the quarter. On average, analysts forecast that Protalix BioTherapeutics, Inc. will post 0.12 earnings per share for the current fiscal year.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.